Mankind Pharma Limited

NSEI:MANKIND Stock Report

Market Cap: ₹1.0t

Mankind Pharma Valuation

Is MANKIND undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MANKIND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₹1.17k
Fair Value
115.1% overvalued intrinsic discount
16
Number of Analysts

Below Fair Value: MANKIND (₹2518.6) is trading above our estimate of fair value (₹1171.01)

Significantly Below Fair Value: MANKIND is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MANKIND?

Key metric: As MANKIND is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MANKIND. This is calculated by dividing MANKIND's market cap by their current earnings.
What is MANKIND's PE Ratio?
PE Ratio50.9x
Earnings₹20.41b
Market Cap₹1.02t

Price to Earnings Ratio vs Peers

How does MANKIND's PE Ratio compare to its peers?

The above table shows the PE ratio for MANKIND vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average34.7x
500124 Dr. Reddy's Laboratories
19.3x-1.2%₹1.0t
ZYDUSLIFE Zydus Lifesciences
22.1x-1.8%₹1.0t
500257 Lupin
38.2x16.5%₹997.9b
500420 Torrent Pharmaceuticals
59.2x23.3%₹1.1t
MANKIND Mankind Pharma
50.9x17.4%₹1.0t

Price-To-Earnings vs Peers: MANKIND is expensive based on its Price-To-Earnings Ratio (50.9x) compared to the peer average (34.7x).

Price to Earnings Ratio vs Industry

How does MANKIND's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$70.95m
524652 Ind-Swift
1.5xn/aUS$9.91m
No more companies available in this PE range
MANKIND 50.9xIndustry Avg. 31.9xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: MANKIND is expensive based on its Price-To-Earnings Ratio (50.9x) compared to the Indian Pharmaceuticals industry average (31.9x).

Price to Earnings Ratio vs Fair Ratio

What is MANKIND's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MANKIND PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio50.9x
Fair PE Ratio42x

Price-To-Earnings vs Fair Ratio: MANKIND is expensive based on its Price-To-Earnings Ratio (50.9x) compared to the estimated Fair Price-To-Earnings Ratio (42x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MANKIND forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹2,518.60
₹2,822.81
+12.1%
11.5%₹3,300.00₹2,150.00n/a16
Jan ’26₹2,881.05
₹2,814.88
-2.3%
11.9%₹3,300.00₹2,275.00n/a16
Dec ’25₹2,561.20
₹2,814.88
+9.9%
11.9%₹3,300.00₹2,275.00n/a16
Nov ’25₹2,680.70
₹2,469.87
-7.9%
15.2%₹3,300.00₹1,900.00n/a15
Oct ’25₹2,578.95
₹2,445.07
-5.2%
14.9%₹3,300.00₹1,900.00n/a15
Sep ’25₹2,487.75
₹2,297.57
-7.6%
10.1%₹2,760.00₹1,900.00n/a14
Aug ’25₹2,004.75
₹2,289.71
+14.2%
9.5%₹2,650.00₹1,900.00n/a14
Jul ’25₹2,160.85
₹2,302.87
+6.6%
10.3%₹2,650.00₹1,800.00n/a15
Jun ’25₹2,139.75
₹2,266.93
+5.9%
9.8%₹2,554.00₹1,800.00n/a14
May ’25₹2,364.40
₹2,199.77
-7.0%
10.9%₹2,520.00₹1,750.00n/a13
Apr ’25₹2,311.90
₹2,197.69
-4.9%
10.9%₹2,520.00₹1,750.00n/a13
Mar ’25₹2,149.35
₹2,184.17
+1.6%
11.2%₹2,520.00₹1,750.00n/a12
Feb ’25₹2,046.25
₹1,937.73
-5.3%
13.0%₹2,300.00₹1,433.00₹2,481.6011
Jan ’25₹1,979.20
₹1,859.00
-6.1%
10.7%₹2,140.00₹1,433.00₹2,881.0511
Dec ’24₹1,914.00
₹1,859.00
-2.9%
10.7%₹2,140.00₹1,433.00₹2,561.2011
Nov ’24₹1,743.60
₹1,853.73
+6.3%
11.0%₹2,190.00₹1,433.00₹2,680.7011
Oct ’24₹1,795.30
₹1,817.82
+1.3%
12.9%₹2,180.00₹1,433.00₹2,578.9511
Sep ’24₹1,716.55
₹1,838.60
+7.1%
12.8%₹2,180.00₹1,433.00₹2,487.7510
Aug ’24₹1,771.20
₹1,626.30
-8.2%
10.0%₹1,875.00₹1,425.00₹2,004.7510
Jul ’24₹1,706.80
₹1,648.67
-3.4%
9.5%₹1,875.00₹1,429.00₹2,160.859
Jun ’24₹1,395.40
₹1,484.50
+6.4%
3.1%₹1,539.00₹1,429.00₹2,139.754
Analyst Price Target
Consensus Narrative from 16 Analysts
₹2.82k
Fair Value
10.8% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 12:01
End of Day Share Price 2025/02/07 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mankind Pharma Limited is covered by 26 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Nitin BhasinAmbit Capital
null nullAntique Stockbroking Ltd.